More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$3.81B
EPS
-4.7
P/E ratio
--
Price to sales
470.52
Dividend yield
--
Beta
0.105805
Previous close
$39.26
Today's open
$39.19
Day's range
$38.23 - $39.47
52 week range
$33.38 - $72.66
show more
CEO
Ian Mortimer
Employees
370
Headquarters
Burnaby, BC
Exchange
NASDAQ Global Market
Shares outstanding
98284734
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Xenon Stock Rises 12% in the Past Month on Pipeline Progress
XENE's shares jump 12% as azetukalner advances, pain candidates deliver encouraging results and a strong cash position supports pipeline growth.
Zacks Investment Research • Nov 17, 2026

Xenon Pharmaceuticals Q3 Earnings Call Highlights
Xenon Pharmaceuticals NASDAQ: XENE expects pivotal depression study results in December, earlier than previously projected, while preparing for a potential U.S. launch of its lead epilepsy drug and advancing two pain treatments into midstage testing.
MarketBeat • Nov 10, 2026

Xenon Pharmaceuticals Inc. (XENE) Q3 2026 Earnings Call Transcript
Xenon Pharmaceuticals Inc. (XENE) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 10, 2026

Xenon Reports Q3 2026 Financial Results and Provides Business Update
New Drug Application for azetukalner in focal seizures submitted to U.S. Food & Drug Administration in September 2026 Expanding potential opportunity in epilepsy through ongoing Phase 3 X-TOLE3 and X-ACKT studies and planned Q1 2027 initiation of Phase 3b/4 X-FIRST study evaluating azetukalner as first add-on ASM Enrollment in Phase 3 X-NOVA2 study of azetukalner in MDD completed with topline data readout now expected in December 2026 Positive Phase 1 data for novel, non-opioid pain programs XEN1701 (Na V 1.7) and XEN1120 (K V 7) presented at IASP World Congress on Pain support initiating Phase 2 proof-of-concept studies in acute pain; studies expected to initiate in H1 2027 Cash, cash equivalents and marketable securities of $1.2 billion with cash runway into 2029 Conference call at 4:30 pm EST today VANCOUVER, BC and BOSTON, MA, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today reported financial results for the third quarter ended September 30, 2026 and provided a business update. “We've made significant progress advancing azetukalner with our recent NDA submission to the FDA for focal seizures and through ongoing scientific exchange opportunities.
GlobeNewsWire • Nov 9, 2026

Xenon to Present at Upcoming Investor Conferences
VANCOUVER, BC and BOSTON, MA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at four upcoming investor conferences in the fourth quarter of 2026.
GlobeNewsWire • Nov 3, 2026

Xenon to Report Q3 2026 Financial Results on November 9, 2026
VANCOUVER, BC and BOSTON, MA, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced it will report its third quarter 2026 financial results and provide a business update after the close of U.S. financial markets on Monday, November 9, 2026. Company Presentation Details: Date: Monday, November 9, 2026 Time: 4:30pm EST (2:30pm PCT) Webcast: Pre-register here Dial-In: (800) 715-9871 toll-free or (646) 307-1963 for international callers Conference ID: 8984105 A live webcast of the company presentation will be available on the Investors section of Xenon's website and posted for replay following the event.
GlobeNewsWire • Nov 2, 2026

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, BC and BOSTON, MA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to nine new non-officer employees consisting of an aggregate of 24,250 share options and 14,250 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company's Board of Directors with an effective date of October 29, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
GlobeNewsWire • Oct 30, 2026

Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain
XEN1701 achieved target profile, including desired Na V 1.7 receptor occupancy in both the peripheral and central nervous system, and was generally well-tolerated with no notable autonomic cardiovascular effects XEN1120 achieved plasma levels predictive of analgesic effects based on preclinical modeling and was generally well-tolerated New preclinical data in cynomolgus monkeys demonstrated significant reductions in capsaicin-evoked heat pain for Na V 1.7 and K V 7 compounds Phase 2 proof-of-concept studies assessing XEN1701 and XEN1120 in acute pain expected to initiate in H1 2027 VANCOUVER, BC and BOSTON, MA, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced positive Phase 1 study results and new preclinical data supporting the advancement of XEN1701 and XEN1120 to Phase 2 proof-of-concept studies in acute pain. Data were presented in two poster presentations during the International Association for the Study of Pain (IASP) 2026 World Congress on Pain, taking place October 26–30, 2026 in Bangkok, Thailand.
GlobeNewsWire • Oct 29, 2026

Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is continuing its investigation into potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: XENE).
GlobeNewsWire • Oct 21, 2026

XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?
Xenon pauses enrollment in late-stage depression trials after unexpected side effects, while its epilepsy pipeline offers growth potential.
Zacks Investment Research • Oct 15, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Xenon Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.